NQMC Update Service: November 5, 2012 ▲ European Society of Breast Cancer Specialists

NQMC Update Service: November 5, 2012

Measure Summaries

European Society of Breast Cancer Specialists

• Breast cancer: proportion of patients with malignant diagnoses in the definitive pathology report.

• Breast cancer: the proportion of invasive cancer cases with primary surgery, for which the following prognostic/predictive parameters have been recorded: histological type; grading (according to EU guidelines); ER & PgR; HER 2; pathological stage (T and N); size in mm for the invasive component; peritumoral vascular invasion; and distance to nearest radial margin.

• Breast cancer: the proportion of non-invasive cancer cases for which the following prognostic/predictive parameters have been recorded: dominant histologic pattern; size in mm (best pathology or radiology estimate if 2 stage pathology); grading (according to EU Guidelines); and distance to nearest radial margin.

• Breast cancer: the proportion of patients (DCIS only) who received just one operation (excluding reconstruction).

• Breast cancer: the proportion of patients (invasive cancer only) who received a single (breast) operation for the primary tumour (excluding reconstruction).

• Breast cancer: the proportion of patients with breast cancer (invasive or in situ) who had a pre-operative definitive diagnosis (B5 or C5).

• Breast cancer: the proportion of patients with DCIS who do not undergo axillary clearance.

• Breast cancer: the proportion of patients with endocrine sensitive invasive carcinoma who received hormonotherapy.

• Breast cancer: the proportion of patients with ER- (T > 1 cm or Node+) invasive carcinoma who received adjuvant chemotherapy.

• Breast cancer: the proportion of patients with invasive breast cancer (M0) who received post-operative radiotherapy after surgical resection of the primary tumour and appropriate axillary staging/surgery in the framework of BCT.

• Breast cancer: the proportion of patients with invasive breast cancer not greater than 3 cm (total size, including DCIS component) who underwent BCT.

• Breast cancer: the proportion of patients with invasive breast cancer with pN0 who do not undergo axillary clearance.

• Breast cancer: the proportion of patients with invasive cancer and axillary clearance performed who had at least 10 lymph nodes examined.

• Breast cancer: the proportion of patients with N+ or N- T > 1 cm HER2+ (IHC 3+ or FISH+) invasive carcinoma treated with chemotherapy and who had adjuvant trastuzumab.

• Breast cancer: the proportion of patients with non-invasive breast cancer not greater than 2 cm who underwent BCT.